Chemotherapy of small cell bronchial cancer with a combination of carboplatin, vincristine and etoposide
Gatzemeier, U.; Achterrath, W.; Heckmayr, M.; Hossfeld, D.K.; Neuhauss, R.; Reck, M.; Zschaber, R.
Pneumologie 44(Suppl 1): 584-585
1990
ISSN/ISBN: 0934-8387 PMID: 2164203 Document Number: 348363
In a phase II study, the combination of the new platinum derivative carboplatin with vincristine and etoposide is associated with a remission rate of 81.8 per cent (LD 84.4%, ED 79.1%). The median survival rates for patients with limited disease have not yet been reached, and, at 11.5 months in the case of patients with extensive disease, are unexpectedly high. In comparison with combinations containing cisplatin, the present combination would appear to be superior, and its toxicity is also lower. For a definitive assessment of its usefulness, it must be compared with other standard treatment regimens in prospective, randomized studies.